Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
29 studies found for:    scFv
Show Display Options
Rank Status Study
1 Completed IMCgp100 in Advanced Unresectable Melanoma
Conditions: Melanoma;   Advanced Disease;   Unresectable
Intervention: Drug: IMCgp100 injection
2 Completed Study of Intra-articular DLX105 Applied to Patients With Severely Painful Osteoarthritis of the Knee
Condition: Osteoarthritis
Interventions: Biological: DLX105, a single-chain (scFv) antibody fragment against TNF-alpha;   Drug: Placebo
3 Unknown  Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Multiple Myeloma;   Acute Myeloid Leukaemia;   Myelodysplastic Syndrome
Intervention: Biological: Anti-LeY- scFv-CD28-ζ vector,.
4 Recruiting Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma
Conditions: Lymphoma;   Lymphoplasmacytic Lymphoma;   Waldenström Macroglobulinemia
Intervention: Biological: DNA Vaccine
5 Completed Ocular Biodistribution Study for Topically Applied ESBA105
Condition: Cataract
Intervention: Drug: Placebo
6 Terminated Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Gastric Cancer;   Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes;   Biological: aldesleukin;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Other: laboratory biomarker analysis;   Other: pharmacological study
7 Recruiting Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia
Conditions: Patients With B Cell ALL, Relapsed or Refractory, With no Available;   Curative Treatment Options (Such as Autologous or Allogeneic Stem Cell;   Transplantation) Who Have Limited Prognosis (> 12 Weeks Survival Expectancy);   With Currently Available Therapies.
Intervention: Biological: CART-19
8 Recruiting CART-BCMA Cells for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: CART-BCMA
9 Active, not recruiting Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma
Condition: Malignant Melanoma
Intervention: Drug: IMCgp100
10 Recruiting CD22 Redirected Autologous T Cells for ALL
Conditions: B Cell Leukemias;   B Cell Lymphomas
Intervention: Biological: CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
11 Recruiting CART19 in Patient With ALL
Condition: Leukemia, Acute Lymphoblastic
Intervention: Biological: CART 19
12 Recruiting Humanized CAR-T Therapy for Treatment of B Cell Malignancy
Condition: Leukemia, Lymphocytic, Chronic, B-Cell
Intervention: Biological: CAR-T
13 Not yet recruiting Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Conditions: Adult Burkitt Lymphoma;   Adult Diffuse Large B-Cell Lymphoma;   CD20-Positive Neoplastic Cells Present;   Indolent Adult Non-Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Refractory Mature B-Cell Non-Hodgkin Lymphoma
Interventions: Biological: Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein;   Radiation: indium In 111-DOTA-biotin;   Radiation: yttrium Y 90 DOTA-biotin;   Drug: Clearing Agent;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
14 Completed Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis
Condition: Anterior Uveitis
Intervention: Biological: ESBA105
15 Recruiting Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies
Condition: Subjects Entering Into This Protocol Will be Followed for up to 15 Years After Initial CART-EGFRvIII Infusion
16 Completed A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours
Condition: Advanced Solid Tumours
Intervention: Drug: L19IL2
17 Active, not recruiting CART-19 for Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Biological: CART-19 T cells
18 Recruiting CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
Conditions: B Cell Lymphoma;   B Cell Leukemia
Intervention: Biological: Autologous 3rd generation CD19-targeting CAR T cells
19 Recruiting CART-meso Long-term Follow-up
Condition: Subjects Who Have Received Lentiviral-based CART-meso Therapy
Intervention: Biological: lentiviral-based CART meso therapy
20 Recruiting Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor
Condition: Solid Tumour
Intervention: Drug: L19-IL2

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Indicates status has not been verified in more than two years